NCT05353179UNKNOWNanonymous

Phase I, Single-center, Randomized, Double-blind, Single-dose, Parallel Comparison of Pharmacokinetic and Safety Similarities Between Meperizumab Injection and NUCALA® in Healthy Male Volunteers

Sponsor

Source record

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase

Source record

Phase I

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Meperizumab injection (humanized monoclonal antibody targeting IL-5 receptor)

Indication / condition

AI-normalized

Granulomatosis With Polyangiitis

Intervention

Source record

Meperizumab injection, NUCALA®

Source & freshness

Source record

NCT ID

NCT05353179

Original source

ClinicalTrials.gov

Source last updated

Apr 29, 2022

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT05353179

Title

Phase I, Single-center, Randomized, Double-blind, Single-dose, Parallel Comparison of Pharmacokinetic and Safety Similarities Between Meperizumab Injection and NUCALA® in Healthy Male Volunteers

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Status

UNKNOWN

Phase

Phase I

Condition raw

Granulomatosis With Polyangiitis

Condition normalized

Granulomatosis With Polyangiitis

Modality raw

Granulomatosis With Polyangiitis

Modality normalized

monoclonal antibody

Target raw

Meperizumab injection (humanized monoclonal antibody targeting IL-5 receptor)

Target normalized

Meperizumab injection (humanized monoclonal antibody targeting IL-5 receptor)

Interventions

Meperizumab injection, NUCALA®

Public preview

Source record

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is conducting a Phase I clinical trial to evaluate the pharmacokinetics and safety of Meperizumab injection compared to NUCALA® in healthy male volunteers. The study aims to enroll 88 subjects and assess the similarity in drug behavior and safety profiles.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase I, Single-center, Randomized, Double-blind, Single-dose, Parallel Comparison of Pharmacokinetic and Safety Similarities Between Meperizumab Injection and NUCALA® in Healthy Male Volunteers

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05353179

Status

UNKNOWN

Phase

Phase I

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedApr 29, 2022

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05353179

Indication

Granulomatosis With Polyangiitis

Modality

monoclonal antibody

Target

Meperizumab injection (humanized monoclonal antibody targeting IL-5 receptor)

Intervention

Meperizumab injection, NUCALA®

Source record